S100P Antibody

What is S100P and why is it significant in cancer research?

S100P is a 95-amino acid calcium-binding protein belonging to the S100 family. It has gained significant attention in cancer research due to its overexpression in multiple cancer types including pancreatic, breast, colon, prostate, lung, and gastric cancers compared to matched normal tissues . S100P stimulates tumor proliferation, survival, invasion, and metastasis progression through both intracellular and extracellular functions . Its expression strongly correlates with poor prognosis in cancer patients, making it both a potential biomarker and therapeutic target . Recent evidence suggests S100P creates an immunosuppressive tumor microenvironment, particularly in pancreatic cancer, indicating its importance in tumor immune evasion mechanisms .

What are the primary applications of S100P antibodies in research?

S100P antibodies serve multiple critical research applications:

These applications enable researchers to study S100P expression patterns, protein interactions, and localization within tissues . Additionally, function-blocking monoclonal antibodies against S100P are used to study and potentially inhibit its extracellular activities in therapeutic contexts .

How does S100P protein structure relate to its function and antibody binding?

Each S100 monomer, including S100P, contains two EF-hand calcium-binding motifs that can coordinate up to two calcium ions or other divalent cations . S100 proteins typically form antiparallel homo- or heterodimers that facilitate binding partner proximity in a calcium-dependent (and sometimes calcium-independent) manner . This structural arrangement is crucial for S100P's functions and impacts antibody binding specificity. Antibodies targeting different epitopes may have varying effects on S100P function, particularly those designed to block the interaction between S100P and its receptors like RAGE (Receptor for Advanced Glycation End products) . Understanding this structure-function relationship is essential when selecting or developing antibodies for specific research applications.

What are the optimal conditions for detecting S100P using antibody-based techniques?

For optimal S100P detection, methodology varies by technique:

Immunohistochemistry (IHC):

• Deparaffinize and rehydrate sections thoroughly

• Use polyclonal anti-S100P antibody at 1:10000 dilution (e.g., Proteintech 11283-1-AP)

• Quantify expression using log2(H-score) for consistent results

• Include both tumor and normal tissue controls for comparison

Western Blotting:

• Use 1:1000 antibody dilution

• Target molecular weight: approximately 10 kDa

• Include positive controls (pancreatic cancer cell lines like BxPC3)

Immunoprecipitation:

• Use 1:50 antibody dilution

• Pre-clear lysates to reduce background

• Validate specificity with appropriate controls

Temperature, incubation time, and buffer conditions should be optimized for each specific antibody and application. For recombinant S100P, studies show effective concentrations typically range from 100-500 nM for in vitro studies .

How can researchers validate the specificity of their S100P antibodies?

Validating S100P antibody specificity requires multiple approaches:

• Positive and negative control tissues/cell lines: Use pancreatic cancer samples/cell lines (e.g., BxPC3) known to express high S100P levels as positive controls, and tissues/cells with minimal expression as negative controls .

• Knockout/knockdown validation: Compare antibody signal between wild-type and S100P-knockout or S100P-knockdown cells to confirm specificity.

• Pre-absorption test: Pre-incubate the antibody with purified recombinant S100P protein before applying to samples. Signal elimination/reduction confirms specificity.

• Cross-reactivity assessment: Test reactivity against other S100 family proteins to ensure no cross-reactivity, particularly with closely related members.

• Multiple antibodies comparison: Use antibodies from different sources or targeting different epitopes to confirm consistent detection patterns .

• RNA-protein correlation: Correlate protein detection with S100P mRNA expression data to further validate specificity .

What are the recommended controls for S100P antibody experiments?

For rigorous S100P antibody experiments, researchers should include:

Positive controls:

• Known S100P-expressing pancreatic cancer cell lines (BxPC3)

• Recombinant S100P protein standards

• Tissue samples with validated high S100P expression

Negative controls:

• Isotype control antibodies to assess non-specific binding

• Tissues/cells with minimal S100P expression

• Primary antibody omission controls

Experimental controls:

• For functional studies, include both S100P stimulation and antibody neutralization conditions

• When examining S100P's relationship with drug resistance, include appropriate vehicle controls

• For studies on S100P's correlation with immune cell infiltration, include relevant immune cell markers

The inclusion of these controls ensures reliable and reproducible results when working with S100P antibodies.

How can S100P antibodies be used to study tumor microenvironment and immune infiltration?

Research indicates S100P plays a critical role in establishing an immunosuppressive tumor microenvironment, particularly in pancreatic cancer. To study this relationship:

• Dual IHC staining: Combine S100P antibodies with immune cell markers (particularly CD8+ T cells) to visualize spatial relationships within the tumor microenvironment .

• Flow cytometry: Use S100P antibodies alongside immune cell markers to quantify correlations between S100P expression and immune cell populations.

• Single-cell analysis: As demonstrated in GSE155698 dataset analysis (41,378 cells from 17 tumor samples), researchers can correlate S100P expression with immune cell infiltration at single-cell resolution .

• Functional assays: Combine S100P antibodies with immune function assays to assess how neutralizing S100P affects T cell activity, particularly CD8+ T cells that show significant negative correlation with S100P expression .

• Checkpoint molecule correlation: Assess relationships between S100P, PD-1/CD274, CTLA4, IDO1, BTLA, LAG3, TIM-3/HAVCR2, and TIGIT to understand S100P's role in checkpoint regulation .

Studies have shown that high S100P expression negatively correlates with immune cell infiltration, particularly CD8+ T cells, suggesting its potential role in immune evasion mechanisms .

What is the current understanding of S100P's role in chemoresistance, and how can antibodies help investigate this?

S100P contributes significantly to chemoresistance in pancreatic cancer. Research approaches using antibodies include:

This research suggests S100P antibodies may have clinical potential beyond research tools, potentially serving as therapeutic agents to overcome chemoresistance.

How do S100P's extracellular functions differ from its intracellular roles, and what implications does this have for antibody selection?

S100P functions through both intracellular and extracellular mechanisms, requiring careful antibody selection strategy:

Extracellular functions:

• Binds to RAGE (Receptor for Advanced Glycation End products) and activates MAPkinase and NFκB pathways

• Promotes cell proliferation when added exogenously (e.g., 100 nM recombinant S100P increases BxPC3 proliferation 1.7-fold)

• Induces phosphorylation of IκBα and secretion of MMP-9, promoting invasion

• Confers protection against chemotherapeutic agents

Intracellular functions:

• Involves calcium binding and regulation of various intracellular processes

• May affect nuclear events and gene expression patterns

• Influences cell cycle regulation and apoptotic pathways

Antibody selection implications:

• Function-blocking antibodies are essential for studying extracellular functions and have therapeutic potential

• Cell-permeable antibodies or alternative approaches are needed to study intracellular functions

• Epitope specificity is crucial, particularly for function-blocking antibodies targeting the S100P-RAGE interaction domain

• For comprehensive studies, researchers may need multiple antibodies targeting different epitopes

Interestingly, Cromolyn has been investigated as an S100P inhibitor, but research shows that specific function-blocking antibodies may have superior efficacy in neutralizing S100P's extracellular activities .

How can S100P antibodies be used as tools for potential cancer diagnostics and prognostics?

S100P antibodies show significant potential for cancer diagnostics and prognostics:

• Diagnostic applications:

  • IHC detection in tissue biopsies shows strong differential expression between pancreatic cancer and normal tissues

  • S100P protein was confirmed by IHC to be highly expressed in pancreatic cancer tissues compared to adjacent normal tissues (P < 0.05)

  • Analysis using the UALCAN platform demonstrated significant S100P protein overexpression in 137 primary tumors compared to 74 normal tissues

• Prognostic applications:

  • Kaplan-Meier analysis and Cox regression demonstrated that S100P expression is significantly associated with poor prognosis in pancreatic cancer patients (P < 0.05)

  • Correlation with immune infiltration patterns, particularly CD8+ T cell exclusion, may provide additional prognostic information

  • Association with tumor mutation burden (TMB) offers another dimension for prognostic assessment

• Potential as liquid biopsy target:

  • Researchers have developed tools for detecting S100P protein as a biomarker in plasma samples

  • This could enable non-invasive monitoring of disease progression and treatment response

The combined diagnostic and prognostic value makes S100P an attractive target for clinical application development.

What insights have emerged regarding the relationship between S100P expression and DNA methylation?

Research reveals a significant relationship between S100P expression and DNA methylation patterns:

• Methylation sites correlation:

  • Higher S100P expression demonstrates negative correlation with methylation levels at multiple specific sites (cg14323984, cg27027375, cg14900031, cg14140379, cg25083732, cg07210669, cg26233331, and cg22266967)

  • These methylation sites are associated with CD8+ T cell infiltration, suggesting epigenetic regulation influences the immune microenvironment

• Regulatory mechanism:

  • DNA methylation is recognized as a well-established mechanism for regulating gene expression

  • The MEXPRESS database (https://www.mexpress.be/) has been used to investigate the relationship between DNA methylation and S100P expression

• Research approach:

  • Researchers correlate S100P expression with DNA methylation status using Spearman correlation algorithm

  • This approach reveals how epigenetic modifications may contribute to S100P overexpression in pancreatic cancer

These findings suggest potential epigenetic therapeutic approaches to modulating S100P expression in cancer, which could be monitored using S100P antibodies.

How are S100P antibodies being developed for therapeutic applications?

Function-blocking anti-S100P monoclonal antibodies show promising therapeutic potential:

• Development approach:

  • Researchers have generated monoclonal antibodies specifically targeting S100P's functional domains

  • These antibodies are designed to block extracellular S100P activities, particularly its interaction with receptors like RAGE

• Demonstrated effects:

  • Anti-S100P mAbs abolished S100P-induced cell proliferation in BxPC3 pancreatic cancer cells

  • Antibodies blocked the protective effect of S100P against Gemcitabine cytotoxicity

  • Treatment reduced tumor growth and liver metastasis formation in xenograft pancreatic tumor models

• Combination therapy potential:

  • S100P mAbs combined with chemotherapeutics (particularly Gemcitabine) showed enhanced efficacy

  • This approach reduced the protective effect of S100P (500 nM) against high-dose Gemcitabine (200 nM)

  • Similar results were observed with combinations of S100P inhibitor Cromolyn and Gemcitabine, though specific mAbs appeared more effective

• Mechanisms of action:

  • Antibodies block extracellular S100P binding to RAGE

  • This prevents activation of downstream MAPkinase and NFκB pathways

  • Inhibition affects tumor cell proliferation, invasion, and chemoresistance mechanisms

These findings highlight S100P antibodies as promising therapeutic agents, particularly in combination with established chemotherapeutics for pancreatic cancer.

What are common challenges when working with S100P antibodies and how can they be addressed?

Researchers frequently encounter these challenges when working with S100P antibodies:

• Cross-reactivity with other S100 family proteins:

  • Challenge: S100 family members share structural similarities

  • Solution: Validate antibody specificity against recombinant S100 family proteins; use epitope-specific antibodies

• Sensitivity limitations in tissues with low expression:

  • Challenge: Detecting S100P in normal tissues or early cancer stages

  • Solution: Employ signal amplification methods; use high-sensitivity detection systems; optimize antigen retrieval protocols

• Background signal in IHC applications:

  • Challenge: Non-specific binding creating false positives

  • Solution: Optimize blocking conditions; titrate antibody dilutions (starting with 1:10000 for IHC); include appropriate controls

• Variability in function-blocking efficacy:

  • Challenge: Inconsistent neutralization of S100P activity

  • Solution: Pre-incubate S100P with antibodies (e.g., 500 nM mAb with 100 nM S100P for 2h) before adding to experimental systems

• Timing of antibody administration in in vivo models:

  • Challenge: Determining optimal treatment schedules

  • Solution: Test various administration protocols; monitor S100P levels in circulation to guide dosing

Addressing these challenges ensures more reliable and reproducible results when working with S100P antibodies.

How should researchers interpret contradictory results involving S100P antibody applications?

When faced with contradictory results using S100P antibodies, consider these methodological approaches:

• Antibody variability assessment:

  • Different antibodies may recognize different epitopes with varying functional consequences

  • Compare monoclonal versus polyclonal antibodies (each has advantages/limitations)

  • Verify epitope location relative to functional domains and binding sites

• Experimental context analysis:

  • S100P functions differently in various cell types; compare results across multiple cell lines

  • Extracellular versus intracellular effects may yield seemingly contradictory outcomes

  • Concentration-dependent effects may explain some contradictions (100 nM versus higher concentrations)

• Methodological reconciliation:

  • Compare antibody detection methods (IHC, Western blot, ELISA) that may have different sensitivities

  • Validate findings using orthogonal techniques (e.g., mRNA expression, functional assays)

  • Integrate single-cell approaches to address cellular heterogeneity confounding population-level results

• Biological complexity considerations:

  • S100P interacts with tumor microenvironment in complex ways

  • Immune context affects interpretation (negative correlation with CD8+ T cells)

  • Chemoresistance effects may vary by drug class and mechanism

Carefully documenting experimental conditions and antibody characteristics is essential for resolving apparent contradictions.

What emerging methods might enhance S100P antibody applications in cancer research?

Several emerging methods promise to advance S100P antibody applications:

• Multiplex imaging technologies:

  • Combining S100P antibodies with markers for immune cells, stromal components, and other cancer biomarkers

  • Technologies like Imaging Mass Cytometry, CODEX, or multiplex immunofluorescence enable simultaneous visualization of S100P with dozens of other markers

  • This approach would enhance understanding of S100P's spatial relationship with immune components, particularly given its negative correlation with CD8+ T cells

• Single-cell proteomics integration:

  • Building on single-cell RNA-seq findings that show S100P predominantly expressed in malignant cells

  • Coupling antibody-based detection with single-cell protein profiling

  • This would resolve cellular heterogeneity issues and reveal how S100P expression varies within tumor populations

• Liquid biopsy applications:

  • Developing highly sensitive assays for detecting extracellular S100P in blood

  • Potential for monitoring treatment response or predicting recurrence

  • Building on existing tools for detecting S100P as a plasma biomarker

• Antibody engineering approaches:

  • Bispecific antibodies targeting both S100P and immune checkpoints

  • Antibody-drug conjugates delivering cytotoxic agents specifically to S100P-expressing cells

  • Engineered antibodies with enhanced tissue penetration properties

These approaches could significantly expand the utility of S100P antibodies in both research and clinical applications.

How might combination strategies with S100P antibodies advance therapeutic approaches?

Innovative combination strategies with S100P antibodies show significant promise:

• Chemotherapy sensitization:

  • S100P antibodies resensitize cancer cells to Gemcitabine and potentially other chemotherapeutics

  • This approach directly counters S100P's protective effect against cytotoxic agents

  • Function-blocking antibodies could be administered prior to or concurrently with chemotherapy

• Immune checkpoint inhibitor combinations:

  • Given S100P's negative correlation with CD8+ T cell infiltration

  • S100P antibodies might enhance response to anti-PD-1/PD-L1 or anti-CTLA4 therapies

  • This approach could address the typically poor response of pancreatic cancers to immunotherapy

• Targeting multiple tumor-promoting pathways:

  • Combining S100P antibodies with RAGE inhibitors or NFκB pathway modulators

  • This multi-pathway approach may overcome resistance mechanisms

  • Similar to the enhanced efficacy observed when combining Cromolyn (S100P inhibitor) with Gemcitabine

• Epigenetic therapy combinations:

  • Given S100P's relationship with DNA methylation

  • Combining S100P antibodies with DNMTi (DNA methyltransferase inhibitors) or other epigenetic modulators

  • This approach could address both S100P expression and function simultaneously

These combination strategies represent promising directions for translating S100P research into effective cancer therapies.